Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
Transforming growth factor-β1 (TGF-β1) plays a dual role in cancer, acting as a tumor suppressor in the early stage of cancer development and as a tumor promoter in the later stage of cancer progression in various cancers. In this study, we investigated the association between genetic polymorphisms...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.697955/full |
id |
doaj-a93856b498c54c75b3be08373029e4a7 |
---|---|
record_format |
Article |
spelling |
doaj-a93856b498c54c75b3be08373029e4a72021-05-25T06:23:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.697955697955Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate CancerMasaki Shiota0Naohiro Fujimoto1Takashi Matsumoto2Shigehiro Tsukahara3Shigehiro Tsukahara4Shohei Nagakawa5Shohei Ueda6Miho Ushijima7Eiji Kashiwagi8Ario Takeuchi9Junichi Inokuchi10Takeshi Uchiumi11Masatoshi Eto12Department of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanDepartment of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanDepartment of Urology, Kyushu University, Fukuoka, JapanTransforming growth factor-β1 (TGF-β1) plays a dual role in cancer, acting as a tumor suppressor in the early stage of cancer development and as a tumor promoter in the later stage of cancer progression in various cancers. In this study, we investigated the association between genetic polymorphisms in TGFB1 and clinicopathological characteristics or oncological outcome in prostate cancer cases treated with androgen-deprivation therapy (ADT) according to metastasis status. Japanese male patients with hormone-sensitive prostate cancer treated with ADT from 1993 to 2005 were included in this study. Genomic DNA was obtained from whole blood samples, and genotyping of TGFB1 (rs2241716 and rs4803455) was performed by PCR-based technique. No significant association between genetic polymorphisms in TGFB1 (rs2241716 and rs4803455) and clinicopathological parameters or prognosis was observed in patients with non-metastatic disease. In patients with metastatic disease, Gleason score in CT/TT carriers (rs2241716) and CA/AA carriers (rs4803455) was unfavorable compared with CC carriers. In addition, the CT/TT alleles in rs2241716 (hazard ratio, 1.82; 95% confidence interval, 1.12–2.94; P = 0.015) and the CA/AA alleles in rs4803455 (hazard ratio, 1.75; 95% confidence interval, 1.03–2.98; P = 0.040) were associated with a higher risk of progression during ADT compared with the CC allele in patients with metastatic disease. TGFB1 genetic variations were associated with adverse characteristics and progression risk in ADT among patients with metastatic disease, but not those with non-metastatic disease, supporting a distinct role of TGF-β signaling between non-metastatic and metastatic prostate cancer.https://www.frontiersin.org/articles/10.3389/fonc.2021.697955/fullandrogen-deprivation therapymetastasisprostate cancerSNPTGFB1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Masaki Shiota Naohiro Fujimoto Takashi Matsumoto Shigehiro Tsukahara Shigehiro Tsukahara Shohei Nagakawa Shohei Ueda Miho Ushijima Eiji Kashiwagi Ario Takeuchi Junichi Inokuchi Takeshi Uchiumi Masatoshi Eto |
spellingShingle |
Masaki Shiota Naohiro Fujimoto Takashi Matsumoto Shigehiro Tsukahara Shigehiro Tsukahara Shohei Nagakawa Shohei Ueda Miho Ushijima Eiji Kashiwagi Ario Takeuchi Junichi Inokuchi Takeshi Uchiumi Masatoshi Eto Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer Frontiers in Oncology androgen-deprivation therapy metastasis prostate cancer SNP TGFB1 |
author_facet |
Masaki Shiota Naohiro Fujimoto Takashi Matsumoto Shigehiro Tsukahara Shigehiro Tsukahara Shohei Nagakawa Shohei Ueda Miho Ushijima Eiji Kashiwagi Ario Takeuchi Junichi Inokuchi Takeshi Uchiumi Masatoshi Eto |
author_sort |
Masaki Shiota |
title |
Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer |
title_short |
Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer |
title_full |
Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer |
title_fullStr |
Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer |
title_full_unstemmed |
Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer |
title_sort |
differential impact of tgfb1 variation by metastatic status in androgen-deprivation therapy for prostate cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-05-01 |
description |
Transforming growth factor-β1 (TGF-β1) plays a dual role in cancer, acting as a tumor suppressor in the early stage of cancer development and as a tumor promoter in the later stage of cancer progression in various cancers. In this study, we investigated the association between genetic polymorphisms in TGFB1 and clinicopathological characteristics or oncological outcome in prostate cancer cases treated with androgen-deprivation therapy (ADT) according to metastasis status. Japanese male patients with hormone-sensitive prostate cancer treated with ADT from 1993 to 2005 were included in this study. Genomic DNA was obtained from whole blood samples, and genotyping of TGFB1 (rs2241716 and rs4803455) was performed by PCR-based technique. No significant association between genetic polymorphisms in TGFB1 (rs2241716 and rs4803455) and clinicopathological parameters or prognosis was observed in patients with non-metastatic disease. In patients with metastatic disease, Gleason score in CT/TT carriers (rs2241716) and CA/AA carriers (rs4803455) was unfavorable compared with CC carriers. In addition, the CT/TT alleles in rs2241716 (hazard ratio, 1.82; 95% confidence interval, 1.12–2.94; P = 0.015) and the CA/AA alleles in rs4803455 (hazard ratio, 1.75; 95% confidence interval, 1.03–2.98; P = 0.040) were associated with a higher risk of progression during ADT compared with the CC allele in patients with metastatic disease. TGFB1 genetic variations were associated with adverse characteristics and progression risk in ADT among patients with metastatic disease, but not those with non-metastatic disease, supporting a distinct role of TGF-β signaling between non-metastatic and metastatic prostate cancer. |
topic |
androgen-deprivation therapy metastasis prostate cancer SNP TGFB1 |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.697955/full |
work_keys_str_mv |
AT masakishiota differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT naohirofujimoto differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT takashimatsumoto differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT shigehirotsukahara differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT shigehirotsukahara differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT shoheinagakawa differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT shoheiueda differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT mihoushijima differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT eijikashiwagi differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT ariotakeuchi differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT junichiinokuchi differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT takeshiuchiumi differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer AT masatoshieto differentialimpactoftgfb1variationbymetastaticstatusinandrogendeprivationtherapyforprostatecancer |
_version_ |
1721427904649232384 |